Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimers disease

Biomarkers in Medicine

Volumn 5, Issue 4, 2011, Pages 411-413

  Lista, Simone ^a   Emanuele, Enzo ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Living Research Sas   (Italy)

Author keywords

Alzheimer's disease; amyloid 1 42; amyloid plaques; biomarker; cerebrospinal fluid; mild cognitive impairment; MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BETA SECRETASE; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 80052062032     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.50     Document Type: Editorial

References (20)

1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 4(5), 316-323 (2008).
2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368(9533), 387-403 (2006). (Pubitemid 44108123)
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002). (Pubitemid 34790756)
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-944 (1984). (Pubitemid 14076461)
5. Hampel H, Shen Y, Walsh DM et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp. Neurol. 223(2), 334-346 (2010).
6. Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr. Med. Chem. 15(8), 766-771 (2008). (Pubitemid 351516792)
7. Prvulovic D, Hampel H. Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin. Chem. Lab. Med. 49(3), 367-374 (2011).
8. Reiman EM, Chen K, Liu X et al. Fibrillar amyloid-b burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106(16), 6820-6825 (2009).
9. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385-393 (2009).
10. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 4(1), 38-48 (2008).
11. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med. 8, 89 (2010).
12. Strozyk D, Blennow K, White LR, Launer LJ. CSF Ab 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4), 652-656 (2003). (Pubitemid 36246085)
13. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fuid Ab42 in humans. Ann. Neurol. 59(3), 512-519 (2006). (Pubitemid 43358072)
14. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2(10), 605-613 (2003). (Pubitemid 37162569)
15. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of b-amyloid peptide signatures in cerebrospinal fuid using immunoprecipitation- mass spectrometry. J. Proteome Res. 5(4), 1010-1016 (2006).
16. Albertini V, Bruno A, Paterlini A et al.: Optimization protocol for amyloid-b peptides detection in human cerebrospinal fuid using SELDI TOF MS. Proteomics Clin. Appl. 4(3), 352-357 (2010).
17. Buerger K, Frisoni G, Uspenskaya O et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp. Gerontol. 44(9), 579-585 (2009).
18. Mueller SG, Weiner MW, Thal LJ et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin. N. Am. 15(4), 869-877, (2005). (Pubitemid 43162384)
19. Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract. Neurol. 10(4), 202-207 (2010).
20. Hampel H, Wilcock G, Andrieu S et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. DOI: 10.1016/j.pneurobio.2010.11.005 (2010) (Epub ahead of print).